Prosecution Insights
Last updated: November 20, 2026

Dennis John Sullivan, USPTO Patent Examiner

Listed by the USPTO as SULLIVAN, DENNIS JOHN

Tech Center 1600 • Art Units: 1642 1646 1674

This examiner grants 58% of resolved cases

Analysis

SULLIVAN, DENNIS JOHN is assigned to tech center 1600 and art unit 1642. The record includes 119 resolved cases, with an allowance rate of 58.0%, interview lift of 48.3%, and a median of 1364 days to allowance. The profile combines a moderate allowance outcome with a strong recorded association between interviews and allowance.

The top companies are Janssen Pharmaceuticals Inc., The Regents of the University of California, and University of Florida Research Foundation Inc. The top firms are BakerHostetler, COOLEY LLP, and ArentFox Schiff, LLP & Memorial Sloan-Kettering. Practitioners may want to prioritize interview preparation where the issues can be narrowed through examiner discussion. The median duration is lengthy, so interview planning should be integrated early rather than reserved for the end of prosecution.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

58.0%
Allow Rate
-2.0% vs TC avg
171
Total Applications
+48.3%
Interview Lift
1364
Avg Prosecution Days
Based on 119 resolved cases, 2023–2026

Rejection Statute Breakdown

6.6%
§101 Eligibility
4.0%
§102 Novelty
41.9%
§103 Obviousness
27.1%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18038321 USE OF INSULIN-LIKE GROWTH FACTORS WITH GAMMA-CHAIN CYTOKINES TO INDUCE HOMEOSTATIC PROLIFERATION OF LYMPHOCYTES Non-Final OA UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
17769171 COMPOSITIONS AND METHODS FOR DETECTING PLXDC1 AND PLXDC2 IN HUMAN TISSUES Final Rejection THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
17286083 Methods to Diagnose and Treat Cancer Using Non-Human Nucleic Acids Final Rejection The Regents of the University of California
18216026 Use of Anti-EGFR/Anti-Met Antibody to Treat Gastric or Esophageal Cancer Non-Final OA Janssen Biotech, Inc.
18300183 Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib, Mephalan and Prednisone Non-Final OA Janssen Biotech, Inc.
18300288 Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and Dexamethasone Non-Final OA Janssen Biotech, Inc.
18565023 COMPOSITIONS AND METHODS TO TRANSFECT, TEST, AND TREAT SKIN CELLS Non-Final OA The Regents of the University of Michigan
18556488 THE IMMUNOMODULATORY LIGAND B7-1 MEDIATES SYNAPTIC REMODELING BY P75NTR Final Rejection Cornell University
18020515 PLASMA EXCHANGE REMOVAL OF SPD-L1 Final Rejection Mayo Foundation for Medical Education and Research
19243836 SUBCUTANEOUS FCRN ANTAGONIST FORMULATIONS AND METHODS OF USE THEREOF Non-Final OA argenx BV
17517567 USE OF ISATUXIMAB FOR THE TREATMENT OF MULTIPLE MYELOMA Final Rejection Sanofi-Aventis U.S. LLC
17797916 COMPOSITION COMPRISING CHEMOKINE INHIBITOR, COLONY STIMULATING FACTOR INHIBITOR, AND CANCER IMMUNOTHERAPY AGENT FOR PREVENTION OR TREATMENT OF CANCER AND COMBINATION THERAPY Non-Final OA AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
17909310 ANTI-CCR8 AGENTS Final Rejection Memorial Sloan Kettering Cancer Center
18280981 USE OF OREGOVOMAB AND BEVACIZUMAB, PACLITAXEL, CARBOPLATIN FOR TREATMENT OF BRCA-WILD TYPE PLATINUM SENSITIVE RECURRENT Non-Final OA CANARIABIO INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Dennis John Sullivan's allowance rate?

58.0% of resolved applications examined by Dennis John Sullivan were allowed (119 resolved cases), compared with 38.5% across Art Unit 1642 over the last five years.

Does an interview help with examiner Dennis John Sullivan?

This examiner's interview lift is +48.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Dennis John Sullivan take to allow a patent?

Applications allowed by Dennis John Sullivan took 1,364 days on average from filing to allowance.

Which art unit does examiner Dennis John Sullivan work in?

Dennis John Sullivan examines applications in Art Unit 1642 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month